Normal glucagon signaling and β-cell function after near-total α-cell ablation in adult mice

F Thorel, N Damond, S Chera, A Wiederkehr… - Diabetes, 2011 - Am Diabetes Assoc
F Thorel, N Damond, S Chera, A Wiederkehr, B Thorens, P Meda, CB Wollheim, PL Herrera
Diabetes, 2011Am Diabetes Assoc
OBJECTIVE To evaluate whether healthy or diabetic adult mice can tolerate an extreme loss
of pancreatic α-cells and how this sudden massive depletion affects β-cell function and
blood glucose homeostasis. RESEARCH DESIGN AND METHODS We generated a new
transgenic model allowing near-total α-cell removal specifically in adult mice. Massive α-cell
ablation was triggered in normally grown and healthy adult animals upon diphtheria toxin
(DT) administration. The metabolic status of these mice was assessed in 1) physiologic …
OBJECTIVE
To evaluate whether healthy or diabetic adult mice can tolerate an extreme loss of pancreatic α-cells and how this sudden massive depletion affects β-cell function and blood glucose homeostasis.
RESEARCH DESIGN AND METHODS
We generated a new transgenic model allowing near-total α-cell removal specifically in adult mice. Massive α-cell ablation was triggered in normally grown and healthy adult animals upon diphtheria toxin (DT) administration. The metabolic status of these mice was assessed in 1) physiologic conditions, 2) a situation requiring glucagon action, and 3) after β-cell loss.
RESULTS
Adult transgenic mice enduring extreme (98%) α-cell removal remained healthy and did not display major defects in insulin counter-regulatory response. We observed that 2% of the normal α-cell mass produced enough glucagon to ensure near-normal glucagonemia. β-Cell function and blood glucose homeostasis remained unaltered after α-cell loss, indicating that direct local intraislet signaling between α- and β-cells is dispensable. Escaping α-cells increased their glucagon content during subsequent months, but there was no significant α-cell regeneration. Near-total α-cell ablation did not prevent hyperglycemia in mice having also undergone massive β-cell loss, indicating that a minimal amount of α-cells can still guarantee normal glucagon signaling in diabetic conditions.
CONCLUSIONS
An extremely low amount of α-cells is sufficient to prevent a major counter-regulatory deregulation, both under physiologic and diabetic conditions. We previously reported that α-cells reprogram to insulin production after extreme β-cell loss and now conjecture that the low α-cell requirement could be exploited in future diabetic therapies aimed at regenerating β-cells by reprogramming adult α-cells.
Am Diabetes Assoc